Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies to SARS-CoV-2

Douglas F. Lake[1*], Alexa J. Roeder[1*], Erin Kaleta[2], Paniz Jasbi[3], Sivakumar Periasamy[4,5] Natalia Kuzmina[4,5] Alexander Bukreyev[4,5,6], Thomas Grys[2], Liang Wu[7], John R Mills[7], Kathrine McAulay[2], Alim Seit-Nebi[8], and Sergei Svarovsky[8]

Affiliations:
1. School of Life Sciences, Arizona State University, Tempe AZ, USA
2. Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology, Scottsdale, AZ, USA
3. College of Health Solutions, Arizona State University, Phoenix AZ, USA
4. Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX USA
5. Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX USA
6. Department of Microbiology and Immunology University of Texas Medical Branch at Galveston, Galveston, TX USA
7. Mayo Clinic Rochester, Department of Laboratory Medicine and Pathology, Rochester, MN USA
8. Axim Biotechnologies Inc, San Diego, CA USA
*Co-first authors

Abstract:

As increasing numbers of people recover from and are vaccinated against COVID-19, tests are needed to measure levels of protective, neutralizing antibodies longitudinally to help determine duration of immunity. We developed a lateral flow assay (LFA) that measures levels of neutralizing antibodies in plasma, serum or whole blood. The LFA is based on the principle that neutralizing antibodies inhibit binding of the spike protein receptor-binding domain (RBD) to angiotensin-converting enzyme 2 (ACE2). The test classifies high levels of neutralizing antibodies in sera that were titered using authentic SARS-CoV-2 and pseudotype neutralization assays with an accuracy of 98%. Sera obtained from patients with seasonal coronavirus did not prevent RBD from binding to ACE2.   As a demonstration for convalescent plasma therapy, we measured conversion of non-immune plasma into strongly neutralizing plasma. This is the first report of a neutralizing antibody test that is rapid, highly portable and relatively inexpensive that might be useful in assessing COVID-19 vaccine immunity.

Introduction

The pandemic caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) continues to be transmitted by person to person spread from its origin in Wuhan, China in December 2019[1–3] . Vaccine trials are ongoing, and preliminary results from at least 2 vaccines appear to elicit protective immunity, but durability of vaccine responses is not known[4].

Molecular tests such as PCR detect SARS-CoV-2 nucleic acid in nasopharyngeal secretions and saliva and are diagnostic of infection[5]. These molecular tests can determine the rate of infection, potential re-infection and, when negative, indicate when patients clear the virus. In response to infection, all immunocompetent hosts generate antibodies against the virus. Patients may have a positive serologic test result as well as a PCR-positive test result if they are early in convalescence[6,2–4]. For SARS-CoV-2, antibodies to spike protein do not always predict recovery from COVID19[7].

Almost everyone infected with SARS-CoV-2 generates antibodies against the virus. However, since not all antibodies are created equal, it is essential to know which individuals generate high levels of neutralizing antibodies (NAbs) so that they can resume normal activities without fear of being re-infected and spreading the virus to others[8–10]. The goal of COVID-19 vaccines is to induce NAbs that prevent infection/re-infection. Additionally, development of NAbs indicates which individuals might be optimal donors for convalescent plasma protocols. Although NAbs are important for elimination of the virus and protection from subsequent infection, it has been reported by several groups that up to one-third of convalescent plasma from individuals who have recovered from COVID-19 do not neutralize SARS-CoV-2 or spike pseudotype virus infection[11–13].

Viral neutralization assays measure levels of antibodies that block infection of host cells. Two main types of viral neutralization assays are utilized for SARS-CoV-2. Authentic neutralization assays measure reduction of viral plaques or infectious foci in microneutralization

assays in susceptible host cells using SARS-CoV-2 under BSL3 conditions. These assays are

slow, laborious, require highly trained personnel and require a BSL3 facility. Pseudotype virus

neutralization assays have been developed in which SARS-CoV-2 spike protein is expressed in

a virus such as vesicular stomatitis virus or lentivirus[14,15]. These assays are faster and less

dangerous than authentic neutralization assays, but still require BSL2 conditions and 24-48

hours for results. Another challenge is that both authentic and pseudovirus virus assays

depend on host cells for infection which adds variability to the assay.

It is known that SARS-CoV-2 uses RBD on spike protein to bind ACE2 on host cells and

appears to be the principal neutralizing domain of SARS-CoV-2[16,17]. Using this knowledge, we

developed an LFA that measures levels of (neutralizing) antibodies which block RBD from

binding to ACE2. Other groups have developed RBD-ACE2-based competition ELISAs[18,19] but

none have developed a rapid, highly portable semi-quantitative point-of-care (POC) test.

Methods

Human Subjects and Samples

Peripheral blood, serum and plasma were collected for this study under an Arizona State

University IRB approved protocol #0601000548 and Mayo Clinic IRB protocol #20-004544.

Plasma was obtained by ficoll gradient separation of peripheral blood and serum was obtained

by centrifugation 30 minutes after drawing blood.   Plasma and serum samples obtained from

excess clinical samples at Mayo Clinic were pre-existing, de-identified and leftover from normal

workflow. COVID-19 samples ranged from 3 to 84 days post PCR diagnosis.

Pseudotype Virus and Authentic SARS-CoV-2 Neutralization Assays

Titers were obtained from 60 COVID-19 patient sera using a VSV spike protein

pseudotype assay as previously reported[14].   Inhibitory concentrations for which 50% of virus is

neutralized by serum antibodies (IC_{50} values) were obtained using a different set of 38 COVID-

19 sera in an authentic SARS-CoV-2 neutralization assay using a recombinant SARS-CoV-2 that expresses mNeonGreen (SARS-CoV-2ng) during replication in permissive cells[20]. Sixty µl aliquots of SARS-CoV-2ng were pre-incubated for 1 h in 5% CO_2 at 37ºC with 60 µl serial 2-fold serum dilutions, and 100 µl were inoculated into Vero-E6 monolayers in black polystyrene 96-well plates with clear bottoms (Corning). Each serum was tested in duplicates. The final amount of the virus was 200 PFU/well, and the starting serum dilution was 1:20. Cells were maintained in Minimal Essential Medium (ThermoFisher Scientific) supplemented by 2% FBS (HyClone) and 0.1% gentamycin in 5% CO_2 at 37ºC. After 2 days of incubation, fluorescence intensity of infected cells was measured at a 488 nm wavelength using a Synergy 2 Cell Imaging Reader (Biotek). The signal readout was normalized to virus control aliquots with no serum added and was presented as the percentage of neutralization. IC_{50} was calculated with GraphPadPrism 6.0 software. Work with infectious SARS-CoV-2ng was performed in a BSL-3 biocontainment laboratory of the Galveston National Laboratory.

Lateral Flow Assay

The LFA contains a test strip composed of a sample pad and blood filter, conjugate pad, nitrocellulose membrane striped with test and control lines, and an absorbent pad to wick excess moisture (Axim Biotechnologies Inc, San Diego, CA). Test strips are secured in a cassette that contains a single sample port (Empowered Diagnostics, Pompano Beach, FL). For procedural control purposes, the LFA also contains a control mouse antibody conjugated to red gold nanospheres and corresponding anti-mouse control line. Thus, a control line should be visible in every assay. In the absence of a developed control line, results are not valid, and the test should be repeated.

The test leverages the interaction between RBD-conjugated green gold nanoshells (Nanocomposix, San Diego, CA) and ACE2, to detect RBD-NAbs in COVID-19 convalescent

plasma (CCP). As indicated by the competitive nature of this assay, test line density is inversely proportional to RBD-NAbs present within the sample. Thus, an absent or faint test line indicates high levels of RBD-NAbs, whereas a dark or strong test line suggests lack of RBD-NAbs within a given plasma sample.

To demonstrate the ability of the test to measure NAbs in whole blood, 10μg of a neutralizing monoclonal antibody (mAb) based on the sequence of B-38[21](Axim Biotechnologies, Inc, San Diego, CA) was mixed with 10μl of normal donor whole blood collected in a heparinized blood collection tube. Two-fold dilutions were made in whole blood to a final concentration of 0.625μg neutralizing mAb. Then, 10μl of each dilution were transferred to LFA cassettes, chased with 50μl running buffer, and read with an LFA reader after 10 minutes.

LFAs were performed at ambient temperature and humidity on a dry, flat surface and left to run undisturbed for 10 minutes prior to reading results. First, 10μL of plasma or whole blood were transferred to the cassette sample port and immediately followed by two drops (~50μL) of chase buffer. After 10 minutes, each test was placed in a Detekt RDS-2500 LFA reader (Austin, TX, USA) and the densities of both test and control lines were recorded electronically.

Conversion of Non-immune Normal Human Plasma (NIHP) into Neutralizing Plasma

To convert NIHP into strongly neutralizing plasma (SNP), plasma from a convalescent donor who demonstrated the ability to block RBD from binding to ACE2 (M21) was mixed with NHP collected prior to December 2019. For example, for a 1% mixture, 1ul of SNP was mixed with 99ul NIHP; for a 5% mixture 5ul of SNP was admixed with 95 ul NIHP, etc. We performed the test with 10ul of 1%, 5%, 10%, and 20% SNP admixed into NIHP.

Data Analysis

To establish and compare the validity of the LFA and the VITROS® Anti-SARS-COV-2 IgG assay (Ortho Clinical Diagnostics), regression analysis using IC_{50} values was performed to evaluate consistency[18] while Bland-Altman plots were constructed to assess agreement and bias[22,23]. Regression analysis was performed using Microsoft Excel (Redmond, WA); Bland-Altman plots were visualized using IBM SPSS (Armonk, NY). For two-group analysis, IC_{50} values corresponding to >240 were categorized as titer of ≥1:320 (neutralizing), whereas IC_{50} values ≤240 were categorized as ≤1:160 (non-neutralizing). Receiver operating characteristic (ROC) analysis was performed to assess classification accuracy, sensitivity, and specificity of the LFA and Ortho methods in assessing neutralizing capacity; optimal cutoffs for each method were established to maximize area under curve (AUC)[24,25]. ROC analysis was conducted using R (version 3.6.2).

Results

The lateral flow assay reported here is a rapid 10-minute POC test. As shown in the schematic in **Figure 1**, this test utilizes serum, plasma or whole blood to semi-quantitatively measure levels of NAbs.

Figure 1. Schematic of Neutralization LFA. Below each graphic is a representative image of a lateral flow strip demonstrating actual line density. Addition of non-COVID19-immune serum or plasma (*top*) does not block binding of RBD-beads to ACE2 resulting in the RBD-bead–ACE2 complex creating a visible line. Addition of moderate titer NAbs to the sample pad creates a weak line (*middle*). Addition of high titer NAbs (> 1:640) blocks binding of RBD-beads to ACE2 such that no line is observed at the test location on the strip (*bottom*). Red control line represents capture of gold nanospheres coupled to a mouse monoclonal antibody.

An example of strong, moderate and non-neutralizing sera is shown in **Figure 2**. As

diagrammed in **Figure 1**, levels of NAbs in serum or plasma are reflected by the intensity of the

test line which can be read on a hand-held densitometer or compared visually to a scorecard

(**Supplemental Figure 1**). Figure 2A is representative of highly neutralizing sera, while Figure

2B and 2C represent moderately neutralizing sera. Figure 2D represents sera that do not

contain NAbs or have undetectable levels of Nabs.

A	B	C	D
$IC_{50} \geq 500$	$250 \leq IC_{50} < 500$	$170 \leq IC_{50} < 250$	$IC_{50} < 170$

Figure 2. RBD-ACE2 Neutralizing Antibody Lateral Flow Assay.   Red control line across from
the "C" on the cassette indicates that the test ran properly and the green test line across from
the "T" can be used to measure the ability of plasma or serum to block RBD on gold nanoshells
from binding to ACE2. **(A)** represents patient serum producing a visually non-existent line with
density units of 10,095 and an $IC_{50} > 500$ ($IC_{50} = 1151$); **(B)** represents patient serum with a line
density of 132,503 and an IC_{50} of 396; **(C)** represents patient serum with a line density of
239,987 and an IC_{50} of 243; (**D)** represents patient serum with a line density of 485,665 and an
IC_{50} of 96.

We tested serum samples with known neutralization titers from a VSV-based spike

pseudotype assay in our LFA. De-identified serum samples were sent from Mayo Clinic

Rochester to our laboratories. Personnel running the LFA were blinded to the titers of each

sample. After de-coding, the LFA tracked with serum titers, especially at higher titers and

correctly distinguished all non-neutralizing serum (**Figure 3A**).

To further support the application of our lateral flow test to measure levels of antibodies

that neutralize SARS-CoV-2, we tested a different set of 38 serum samples that were assigned

IC_{50} values in an authentic SARS-CoV-2 neutralization assay[20]. Again, the experiment was performed in a blinded manner such that personnel running either the LFA or the microneutralization assay did not know the results of the comparator test. When line densities from the LFA are plotted against IC_{50} values determined in the SARS-CoV-2 microneutralization assay, serum samples with strong neutralization activity also demonstrate low line densities which indicates inhibition of RBD from binding to ACE2 (**Figure 3B**).

Figure 3. (A) Comparison of RBD-ACE2 competition LFA Density Units with VSV-Spike pseudotype virus assay titers using convalescent sera. Titers from the pseudotype assay are shown on the X-axis. Scatter plots with bar graph including standard deviation of the mean for 10 serum samples at each titer except for negative donor serum which is eight samples. **(B)** Comparison of RBD-ACE2 competition LFA with IC_{50} values determined in a SARS-CoV-2 microneutralization assay with a different set of COVID-19 patient serum samples. Ranges of IC_{50} values are shown on the X-axis plotted against LFA line density units on the Y-axis. Thirty-eight serum samples from Mayo Clinic Biobank ranging from 3 to 90 days after PCR-based diagnosis were tested.

Next, we determined if our test detected any neutralization activity in serum samples collected from patients with other respiratory viruses including seasonal coronaviruses (**Figure 4**). None of the seasonal respiratory virus plasma samples, including PCR-confirmed seasonal coronavirus samples showed neutralizing activity.

Plasma from seasonal respiratory virus infections

Figure 4. Plasma samples collected with PCR-confirmed diagnosis of seasonal respiratory viruses (OC43, blue; HKU-1, green; NL-63, pink; influenza A, orange, influenza B, red ; parainfluenza, purple ; rhinovirus, teal ; respiratory syncycial virus, yellow ; and adenovirus, black were run on the LFA as described in Methods. A positive control serum from a convalenscent COVID-19 patient is shown on the far right of the bar graph in white. Cutoff value of 263,000 density units was calculated based on receiver operating characteristic curves in a later figure.

We evaluated how the Ortho assay and our LFA compared to IC_{50} values determined in an authentic SARS-CoV-2 neutralization assay using 38 COVID-19 sera (different from the 60 sera in **Figure 3A** with known titers). FDA guidance indicates that an Ortho VITROS SARS-CoV-2 IgG assay of ≥12 meets a threshold for convalescent plasma use in patients with COVID-19. To determine the agreement between our lateral flow assay and the Ortho VITROS SARS-CoV-2 IgG assay, density units from our LFA and values from the Ortho test were regressed onto IC_{50} values (**Figure 5**). LFA values accounted for roughly 52% of observed variance in IC_{50} values, while Ortho VITROS accounted for approximately 27% of IC_{50} variance. Since the format of the LFA reports decreasing density values as neutralization increases, LFA was significantly inversely correlated with IC_{50} values (r = -0.720, p < 0.001), while Ortho values showed a significant positive correlation to IC_{50} values (r = 0.522, p = 0.001). Additionally, LFA and Ortho values showed a

significant relationship with each other (r = -0.572, p < 0.001). To evaluate bias between the assays, mean differences and 95% confidence intervals (CIs) were calculated and plotted alongside limits of agreement (**Figure 6**).

Figure 5. Regression analysis between **(A)** LFA and serum titer, and **(B)** Ortho VITROS and titer. Regression plots show explained variance (R^2) between compared methods.

Figure 6. Bland-Altman plots showing bias (mean difference and 95% CI) and computed limits of agreement (mean difference ± 2SD) between **(A)** Ortho Vitros IgG assay and IC_{50} values and **(B)** our LFA and IC_{50} values.

Both LFA and Ortho values showed high agreement with titer, although Ortho showed a tendency to underestimate neutralizing capacity while the LFA method showed no bias. As can be seen in **Figure 7B** and **7D**, the LFA misclassified one non-neutralizing sample (Neg—1:160) as neutralizing (≥1:320). In contrast, Ortho misclassified that same non-neutralizing sample as neutralizing, in addition to incorrectly classifying five additional neutralizing samples as non-

neutralizing. Importantly, our LFA method exhibited a greater dynamic range of differential values as compared to Ortho (**Figure 6**), translating to superior classification accuracy of the LFA method in detecting neutralizing samples (titer ≥ 1:320) compared to Ortho (**Figure 7A** and **7C**).

Figure 7. **(A)** Univariate ROC analysis of Ortho for discrimination of neutralizing samples (≥1:320) [AUC: 0.856, 95% CI: 0.697—0.953, sensitivity = 0.7, specificity = 0.9]. **(B)** Box plot of Ortho values between neutralizing (≥1:320) and non-neutralizing (Neg—1:160) groups. **(C)** Univariate ROC analysis of LFA for discrimination of neutralizing samples (≥1:320) [AUC: 0.978, 95% CI: 0.908—1.0, sensitivity = 1.0, specificity = 0.9]. **(D)** Box plot of LFA values between neutralizing (≥1:320) and non-neutralizing (Neg—1:160) groups.

Univariate ROC analysis was performed to assess the performance of the newly developed LFA and Ortho assay to classify non-neutralizing (Neg—1:160), and neutralizing groups (≥1:320) (**Figure 7**). Our LFA showed high accuracy for classification of neutralizing

samples (AUC = 0.978), while the Ortho assay showed modest accuracy for classification of neutralizing samples (AUC = 0.856). Furthermore, while the LFA method showed a narrow confidence interval (95% CI: 0.908—1.00), ROC analysis of Ortho values showed a wider range (95% CI: 0.697—0.953), indicating less certainty. Notably, while both methods showed roughly 90% specificity, Ortho showed only 70% sensitivity. In contrast, the novel LFA method showed perfect sensitivity (100%) in this analysis of 38 samples.

Optimal cutoffs were computed to maximize AUC. For the LFA, density unit values below 263,000 classify samples as neutralizing and correspond to titers ≥1:320. Density unit values above this LFA cutoff classify samples in the non-neutralizing group. For the Ortho assay, values between 0 and 23.3 were representative of non-neutralizing capacity, whereas values above 23.3 were reflective of the neutralizing group. If we used the FDA cutoff of 12 instead of the 23.3 value calculated using our results, AUC would be reduced to 0.69 (sensitivity = 0.55, specificity = 0.83).

The principle of infusing convalescent plasma from recovered individuals into patients fighting COVID19 is to transfer NAbs from the donor to the recipient as has been done for several other diseases[26–28]. The rapid test described here, could quickly and efficiently classify COVID19 convalescent plasma (CCP) units so that the sickest patients might receive the most potently neutralizing plasma. Although levels of neutralizing antibody to achieve in patients receiving CCP remains undefined, our point-of-care test might be useful at the bedside to monitor a patient receiving highly neutralizing CCP as he/she begins to demonstrate NAbs in circulation, as shown in **Figure 8A**. It could help in deciding whether to administer another unit of highly neutralizing CCP to a patient fighting COVID19. The same scenario might also be applied to hyperimmune gammaglobulin or neutralizing monoclonal antibody infusion.

To demonstrate the utility of our LFA to measure NAbs in whole blood, we used a lateral flow strip with a blood filter and performed an experiment in which a neutralizing monoclonal antibody based on the B-38[21] sequence was titrated into whole blood as shown in **Figure 8B**. Density units were not obtained in these experiments but both **Figures 8A** and **8B** demonstrate

the semi-quantitative nature of this test to visually distinguish different levels of NAbs in plasma

and whole blood.

Figure 8. (A) Highly neutralizing plasma (M21) converts normal human plasma (ND82) into highly neutralizing plasma; 10μl of plasma was added to each lateral flow cassette. Text below each lateral flow cassette indicates the percent M21 and percent ND82 plasma used to run the lateral flow test. **(B)** Titration of anti-RBD neutralizing mAb into 10μl of heparinized whole blood. For both types of cassettes, plasma or blood sample was immediately chased with 50μl sample buffer. Densities were read and cassettes were imaged after 10 minutes development.

Discussion

Serologic tests that detect responses to infection are an important population

surveillance tool during pandemics because they provide data on pathogen exposure, especially

when a subset of the population is asymptomatic and would not have been diagnosed by molecular methods[29,30]. While over 90% of individuals diagnosed with COVID19 generate antibody responses[29] we are only beginning to learn about the prevalence and duration of NAbs induced by a natural infection. This lack of knowledge is mainly due to the fact that virus-based neutralization assays require *i)* BSL2 or BSL3 facilities, *ii)* highly skilled personnel, *iii)* permissive cells and quantified virus, and *iv)* take longer than 24 hours to obtain results. Since every viral vaccine, including COVID19 vaccines, administered to humans is designed to elicit antibodies that neutralize virus by blocking host cell infection, development of NAbs is a hallmark of protection from disease. Therefore, there is a need for rapid, accurate tests that measure levels of NAbs.

We developed a rapid, 10-minute lateral flow test that measures levels of NAbs in serum and plasma. As shown in **Figure 3**, the lateral flow test correlates well with serologic titers determined using a VSV-based pseudotype assay, and IC_{50} values in an authentic SARS-CoV-2 microneutralization assay, especially when serum sample titers are ≥640 and IC_{50} values are >250. Samples with less potent NAbs in both viral assays correlated with decreased ability to block RBD from binding to ACE2 in the LFAs.

The LFA and Ortho methods showed a strong, significant correlation with each other (r = -0.572, p < 0.001), displaying an appreciable degree of linear relation[31]. Importantly, LFA accounts for 52% of observed IC_{50} variance (R^2 = 0.5187) while, in comparison, Ortho accounts for 27% (R^2 = 0.2725). Although absolute quantitation of a construct demands an excellent coefficient of determination ($R^2 \geq 0.99$)[32], variables with $R^2 \geq 0.5$ are highly predictive in univariate regression models while measures with $R^2 < 0.5$ are recommended for use in multivariate models in combination with complementary measures to increase predictive accuracy[33,34]. Additionally, Bland-Altman analysis (**Figure 6**) showed Ortho to be prone to underestimation of IC_{50} values. In contrast, the LFA method did not exhibit any over- or underestimation bias. Furthermore, across

mean values for both methods, LFA showed discrete differential values while Ortho struggled to differentiate samples with high neutralizing capacity (IC_{50} values).

Since the Ortho Vitros IgG assay uses S1, which includes RBD, it is likely that antibodies reactive with other parts of S1–even some that may neutralize via N-terminal domain–are responsible for increased reactivity to S1 when they are not neutralizing in our RBD-ACE2 competition assay. Advantages of our POC test is that it can be inexpensively and rapidly deployed in studies to determine levels of NAbs that protect against re-infection and limit transmission of the virus. Moreover, rapid inexpensive tests can be used longitudinally to evaluate duration of protective immunity in both naturally infected and many more vaccinated individuals than could ever be evaluated using BSL2 or BSL3-based neutralization assays.

In the setting of much debated CCP, a rapid test could be used to measure levels of NAbs in a CCP product prior to infusion, or potential donors who recovered from COVID-19. During infusion of CCP, a rapid test could be used to help decide if a patient fighting COVID-19 requires another unit of highly neutralizing plasma. If a particular donor's CCP has very high levels of CCP, patients might need only one unit. On the other hand, if donor CCP contains moderate levels of NAbs, the patient may require multiple units to achieve therapeutic levels of NAbs. However, since we do not know what an adequate therapeutic dose of NAbs is, this rapid test could be a valuable tool in trials to determine under what conditions CCP, hyperimmune globulin, and neutralizing mAbs are effective therapeutic agents for COVID19 patients.

Limitations of the LFA are that it uses only the RBD portion of SARS-CoV-2 spike protein. Although the vast majority of reports indicate that the principle neutralizing domain is RBD portion of spike protein, mAbs have been reported that neutralize SARS-CoV-2 by binding

to the N-terminal domain of spike protein[35,36]. Also, since the spike protein assumes several conformations during viral binding and entry[37], neutralizing epitopes exist on the quaternary structure of spike[36]. Although RBDs on the nanoparticles may associate, it is unlikely they assume a native quaternary conformation.

Other limitations are the binary nature of the data analysis (neutralizing and non-neutralizing) of a continuous assay. Clearly, line densities demonstrate moderate levels of neutralization. Since blood draws and subsequent assays are a "snapshot in time" of neutralizing antibody activity, levels were undoubtedly increasing in some patients and decreasing in others. LFAs are generally inexpensive and highly portable compared to other laboratory-based tests, so neutralizing antibody levels could be measured using the LFA to longitudinally assess protective neutralizing antibody immunity. Another limitation is that the LFA does not differentiate high affinity anti-RBD NAbs from an abundance of lower affinity anti-RBD NAbs. In related experiments, we have observed patient sera that bind strongly to RBD, but do not demonstrate neutralizing activity (data not shown).

This test may prove very useful in monitoring COVID-19 vaccine recipients. Although vaccines have now been approved for distribution and administration, durability of protective immunity elicited by any COVID-19 vaccine is unknown. It is the goal of all COVID-19 vaccines to induce protective NAbs. However, since clinical trials of vaccines have enrolled 30,000 to 60,000 participants, it is not logistically possible to draw a tube of blood from each vaccine recipient longitudinally to determine duration of protective NAbs. Application of our test in vaccine recipients using a drop of blood obtained from a finger-stick as shown in **Figure 8B** might lead to more comprehensive longitudinal monitoring of increases and decreases in protective humoral immunity.

Supplemental Figures

Supplemental Figure 1: Scorecard for measuring relative levels of NAbs in plasma or serum.

Density Unit Range: <50,000   50,000-150,000   150,000-450,000   >450,000

Actual Line Density: 10095   132503   317156   645040

| $IC_{50} \geq 500$ | $250 \leq IC_{50} < 500$ | $170 \leq IC_{50} < 250$ | $IC_{50} < 170$ |

References

1. Ghinai, I. *et al.* First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. *The Lancet* **395**, 1137–1144 (2020).
2. Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* **395**, 497–506 (2020).
3. Li, R. *et al.* Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science* **368**, 489–493 (2020).
4. Widge, A. T. *et al.* Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. *N Engl J Med* 4 (2020).
5. Loeffelholz, M. J. & Tang, Y.-W. Laboratory diagnosis of emerging human coronavirus infections – the state of the art. *Emerg. Microbes Infect.* **9**, 747–756 (2020).
6. Yongchen, Z. *et al.* Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. *Emerg. Microbes Infect.* **9**, 833–836 (2020).
7. McAndrews, K. M. *et al. Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding domain does not predict rapid recovery from COVID-19*. http://medrxiv.org/lookup/doi/10.1101/2020.05.01.20087684 (2020) doi:10.1101/2020.05.01.20087684.
8. Han, Z., Battaglia, F. & Terlecky, S. R. Discharged COVID-19 Patients Testing Positive Again for SARS-CoV-2 RNA: A Minireview of Published Studies from China. *J. Med. Virol.* jmv.26250 (2020) doi:10.1002/jmv.26250.
9. Ye, G. *et al.* Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. *J. Infect.* **80**, e14–e17 (2020).
10. Hoang, V. T., Dao, T. L. & Gautret, P. Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19. *J. Med. Virol.* jmv.26056 (2020) doi:10.1002/jmv.26056.
11. Robbiani, D. F. *et al. Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals*. http://biorxiv.org/lookup/doi/10.1101/2020.05.13.092619 (2020) doi:10.1101/2020.05.13.092619.
12. Juno, J. A. *et al. Immunogenic profile of SARS-CoV-2 spike in individuals recovered from COVID-19*. http://medrxiv.org/lookup/doi/10.1101/2020.05.17.20104869 (2020) doi:10.1101/2020.05.17.20104869.
13. Wu, F. *et al.* Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *MedRxiv Prepr.* 20 (2020) doi:https://doi.org/10.1101/2020.03.30.20047365.
14. Vandergaast, R. *et al. Development and validation of IMMUNO-COV^{TM}: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2*. http://biorxiv.org/lookup/doi/10.1101/2020.05.26.117549 (2020) doi:10.1101/2020.05.26.117549.
15. Crawford, K. H. D. *et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays*. http://biorxiv.org/lookup/doi/10.1101/2020.04.20.051219 (2020) doi:10.1101/2020.04.20.051219.
16. Wang, Q. *et al.* Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. *Cell* S009286742030338X (2020) doi:10.1016/j.cell.2020.03.045.

17. Premkumar, L. *et al.* The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci. Immunol.* **5**, eabc8413 (2020).
18. Tan, C. W. *et al.* A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. *Nat. Biotechnol.* (2020) doi:10.1038/s41587-020-0631-z.
19. Hanson, Q. M. *et al. Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay*. http://biorxiv.org/lookup/doi/10.1101/2020.06.16.154708 (2020) doi:10.1101/2020.06.16.154708.
20. Xie, X. *et al.* An Infectious cDNA Clone of SARS-CoV-2. *Cell Host Microbe* **27**, 841-848.e3 (2020).
21. Wu, Y. *et al.* A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. *Science* **368**, 1274–1278 (2020).
22. Davide Giavarina. Understanding Bland Altman analysis. *Biochem. Medica* **25**, 141–151 (2015).
23. Doğan, N. Ö. Bland-Altman analysis: A paradigm to understand correlation and agreement. *Turk. J. Emerg. Med.* **18**, 139–141 (2018).
24. Obuchowski, N. A. & Bullen, J. A. Receiver operating characteristic (ROC) curves: review of methods with applications in diagnostic medicine. *Phys Med Biol* 29 (2018).
25. Nakas, C. T. & Yannoutsos, C. T. Ordered multiple-class ROC analysis with continuous measurements. *Med. Stat.* **23**, 3437–49 (November 30).
26. Leider, J. P., Brunker, P. A. R. & Ness, P. M. Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?: CONVALESCENT TRANSFUSION FOR PANDEMIC INFLUENZA. *Transfusion (Paris)* **50**, 1384–1398 (2010).
27. Yeh, K.-M. *et al.* Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. *J. Antimicrob. Chemother.* **56**, 919–922 (2005).
28. Enria, D., Briggiler, A., Fernandez, N., Levis, S. & Maiztegui, J. Importance of dose of neutralising antibodies in treatment of Agentine Haemorrhagic Fever with immune plasma. *The Lancet* 255–256 (1984).
29. Gudbjartsson, D. F. *et al.* Humoral Immune Response to SARS-CoV-2 in Iceland. *N. Engl. J. Med.* NEJMoa2026116 (2020) doi:10.1056/NEJMoa2026116.
30. Lee, S. *et al.* Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea. *JAMA Intern. Med.* (2020) doi:10.1001/jamainternmed.2020.3862.
31. Schober, P., Boer, C. & Schwarte, L. A. Correlation Coefficients: Appropriate Use and Interpretation. *Anesth. Analg.* **126**, 1763–1768 (2018).
32. Rights, J. D. & Sterba, S. K. Quantifying explained variance in multilevel models: An integrative framework for defining R-squared measures. *Psychol. Methods* **24**, 309–338.
33. Rights, J. D. & Sterba, S. K. A framework of R-squared measures for single-level and multilevel regression mixture models. *Psychol. Methods* **23**, 434–457.
34. Rights, J. D. & Sterba, S. K. New Recommendations on the Use of R-Squared Differences in Multilevel Model Comparisons. *Multivar. Behav. Res.* **55**, 568–599.
35. Chi, X. *et al.* A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science* eabc6952 (2020) doi:10.1126/science.abc6952.
36. Liu, L. *et al.* Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature* **584**, 450–456 (2020).
37. Cai, Y. *et al.* Distinct conformational states of SARS-CoV-2 spike protein. *Science* eabd4251 (2020) doi:10.1126/science.abd4251.